Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vivani Medical, Inc. filings on SEC EDGAR ↗
Vivani Medical entered into a share purchase agreement for a $5.1 million private placement of common stock with board members Gregg Williams and Aaron Mendelsohn. The shares were priced at $1.01 per share, representing an at-the-market transaction based on the prior trading day's close. Proceeds will be used to fund the clinical development of NPM-139, the company's semaglutide implant for weight maintenance.
Vivani Medical announced positive top-line results from its SLIM-1 Phase 1 trial evaluating NPM-139, a miniature semaglutide implant for chronic weight management. The trial demonstrated that NPM-139 was well-tolerated with no treatment-related adverse events and achieved weight loss of 0.79% over four weeks, comparable to the 0.82% observed in the Wegovy control group.
Term
4 weeks
“The third quarter and recent weeks mark a period of strong progress and forward momentum for Vivani. The top-line SLIM-1 results will be announced this week. We look forward to sharing those results with shareholders, industry peers, and the broader community of physicians and patients seeking less frequent dosing and the promise of potential improvements in convenience, medication adherence, and tolerability associated with GLP-1 therapies on the market and in clinical-stage development.”
Adam Mendelsohn, PhD, CEO
“Roughly half of patients don’t take their medications for chronic diseases as prescribed, and GLP-1 therapies are no exception. With NPM-139, we are designing a novel GLP-1 therapy that a patient could receive once or twice a year during a routine primary care visit.”